Opinions
Gordon Reid
Parexel International Corp.
PRXL-Q
PAST TOP PICK
Feb 17, 2010
(Top Pick Mar 11/09, Up 163.6%) Not as cheap as it was, but still good value.
$20.350
Stock price when the opinion was issued
biotechnology
pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
TOP PICK
A contract research organization that basically takes outsourced clinical studies on behalf of pharmaceuticals, runs the studies through various phases on behalf of them. They have $5.4 billion of backlog. Have just gone through a restructuring process which will be additive in the last half of this year to their earnings.
biotechnology
pharmaceutical
PAST TOP PICK
(A Top Pick March 23/16. Up 9%.) Does clinical trials for the major drug producers, which is about 75% of their business. It’s been mildly disappointing. A very good company. They are growing their cash, which may lead to a dividend being paid in the near future. Very active in buying back shares. It has lots of potential.
biotechnology
pharmaceutical
Advertising